Compare Stocks: PRAX, BIIB, ALNY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$240.63 0.0%	$261.71	$197.81 ▼ $495.55	$32.30B	0.3	1.43 million shs	1,264 shs
BIIB Biogen	$218.22 +0.7%	$208.15	$133.53 ▼ $222.85	$32.18B	0.17	1.22 million shs	2,197 shs
BNTX BioNTech	$101.16 -0.4%	$95.63	$79.52 ▼ $124.00	$25.57B	1.27	1.11 million shs	10,645 shs
PRAX Praxis Precision Medicines	$353.74 +1.0%	$335.96	$37.19 ▼ $392.70	$9.88B	2.78	464,370 shs	2,478 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.51%	+1.98%	+17.11%	-15.88%	-46.10%
BIIB Biogen	-0.85%	-0.67%	+6.75%	+14.73%	+63.86%
BNTX BioNTech	-0.45%	-9.94%	+12.18%	+13.99%	+1.61%
PRAX Praxis Precision Medicines	+1.61%	-4.82%	+13.80%	+35.73%	+669.21%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$240.63 0.0%	$261.71	$197.81 ▼ $495.55	$32.30B	0.3	1.43 million shs	1,264 shs
BIIB Biogen	$218.22 +0.7%	$208.15	$133.53 ▼ $222.85	$32.18B	0.17	1.22 million shs	2,197 shs
BNTX BioNTech	$101.16 -0.4%	$95.63	$79.52 ▼ $124.00	$25.57B	1.27	1.11 million shs	10,645 shs
PRAX Praxis Precision Medicines	$353.74 +1.0%	$335.96	$37.19 ▼ $392.70	$9.88B	2.78	464,370 shs	2,478 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+1.51%	+1.98%	+17.11%	-15.88%	-46.10%
BIIB Biogen	-0.85%	-0.67%	+6.75%	+14.73%	+63.86%
BNTX BioNTech	-0.45%	-9.94%	+12.18%	+13.99%	+1.61%
PRAX Praxis Precision Medicines	+1.61%	-4.82%	+13.80%	+35.73%	+669.21%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.88	Moderate Buy	$386.14	60.47% Upside
BIIB Biogen	2.58	Moderate Buy	$227.79	4.38% Upside
BNTX BioNTech	2.74	Moderate Buy	$127.44	25.98% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$585.95	65.65% Upside

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	ALNY Alnylam Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$142.00 ➝ $136.00
8/25/2026	BIIB Biogen	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$240.00 ➝ $260.00
8/25/2026	ALNY Alnylam Pharmaceuticals	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$376.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/19/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$318.00
8/18/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$4.80B	6.70	$2.84 per share	84.80	$5.97 per share	40.31
BIIB Biogen	$10.03B	3.22	$22.61 per share	9.65	$124.45 per share	1.75
BNTX BioNTech	$3.25B	7.88	$1.32 per share	76.45	$96.59 per share	1.05
PRAX Praxis Precision Medicines	$8.55M	1,155.13	N/A	N/A	$34.85 per share	10.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	44.86	24.94	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.54	13.56	6.81	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest PRAX, BIIB, ALNY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
BNTX BioNTech	0.01	7.85	7.80
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
BNTX BioNTech	19.20%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

PRAX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

August 31 at 8:03 AM | barrons.com

Bank of New York Mellon Corp Makes New $28.58 Million Investment in Praxis Precision Medicines, Inc. $PRAX

August 30 at 3:20 AM | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Buy" from Brokerages

August 27, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High - What's Next?

August 18, 2026 | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17, 2026 | finance.yahoo.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% Higher - Still a Buy?

August 17, 2026 | marketbeat.com

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

August 16, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

August 12, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Equities Analysts Offer Predictions for PRAX Q3 Earnings

August 11, 2026 | marketbeat.com

Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX

August 10, 2026 | marketbeat.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

August 8, 2026 | theglobeandmail.com

Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating

August 8, 2026 | marketbeat.com

Praxis signals two FDA decisions in ~six months, targets ~$10B ulixacaltamide peak sales while building a ~300-person field force

August 7, 2026 | seekingalpha.com

Praxis: Commercial Launch Could Smash Expectations (Video)

August 7, 2026 | seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX

August 7, 2026 | marketbeat.com

Praxis Precision Medicines Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$240.63 -0.06 (-0.03%)

As of 09:40 AM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$218.22 +1.57 (+0.72%)

As of 09:40 AM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$101.16 -0.45 (-0.44%)

As of 09:40 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Praxis Precision Medicines NASDAQ:PRAX

$353.74 +3.44 (+0.98%)

As of 09:40 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRAX, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRAX, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRAX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRAX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools